Skip to main content
OpenTrials
Completed

NCT Number: NCT05638711

Built-in Calculator Optimizes Continuous Veno-venous Hemofiltration Prescription and Improves Therapeutic Quality in Critically-ill Acute Kidney Injury Patients

The goal of this observational study is to compare in ICU patients received CVVH treatment. The main questions it aims to answer are:

Control of Filtration fraction by built-in calculator

* Reduced filter clotting and prolong filter lifespan * Improve patient mortality Participants will divided into before group and after group based on the day when built-in calculator for calculating Filtration fraction was utilized.

Researchers will compare before group to see if there were differences in clotting events, filter downtime, filter lifespan, mortality, etc.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

CVVH Built-in Culculator Filtration Fraction

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Shuang-Ho Hospital

New Taipei City, Zhonghe District, 23561, Taiwan

About this study

# built-in calculator for calculating Filtration fraction

  • The calculator was built in prescription system since 2020/10/01
  • providing tempt filtration fraction for operators to adjust CVVH dose
  • the protocol of patient care didn't change between before and after group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ICU patients received CVVH during 2019~2021 (3 years) in our hospital

Exclusion criteria

  • under age of 20, pregnant, or with HIV infection

Treatment and study plan

Built-in calculator to calculate Filtration fraction

Device

A calculator built in electronic CVVH prescription system to calculate Filtration fraction

Primary outcomes

  1. Mortality

    Time frame: 30 days, 60 days, "through study completion, an average of 1.5 year" mortality in ICU and in Hospital

    Patient death

Secondary outcomes

  1. Filter clotting events

    Time frame: "through the complete treatment course hours, an average of 24 hours"

    Filter clotting events

  2. Filter lifespan

    Time frame: "through the complete treatment course hours, an average of 24 hours"

    average treatment time per filter

  3. electrolytes_1

    Time frame: the last record received before CVVH (in an average of 1 hour), the first record received CVVH after 24 hours, the first record received after CVVH (in an average of 1 hour)

  4. electrolytes_2

    Time frame: the last record received before CVVH (in an average of 1 hour), the first record received CVVH after 24 hours, the first record received after CVVH (in an average of 1 hour)

    K

  5. electrolytes_3

    Time frame: the last record received before CVVH (in an average of 1 hour), the first record received CVVH after 24 hours, the first record received after CVVH (in an average of 1 hour)

    Ca

  6. electrolytes_4

    Time frame: the last record received before CVVH (in an average of 1 hour), the first record received CVVH after 24 hours, the first record received after CVVH (in an average of 1 hour)

    P

  7. acid-base balance_1

    Time frame: the last record received before CVVH (in an average of 1 hour before CVVH treatment), the first record received CVVH after 24 hours (in an average of 1 hour after CVVH treatment), the first record received after CVVH (in an average of 1 hour after CVVH)

    pH

  8. acid-base balance_2

    Time frame: the last record received before CVVH (in an average of 1 hour before CVVH treatment), the first record received CVVH after 24 hours (in an average of 1 hour after CVVH treatment), the first record received after CVVH (in an average of 1 hour after CVVH)

    bicarbonate

  9. Filter downtime

    Time frame: "through the complete treatment course hours, an average of 24 hours"

    downtime between filter replacement

  10. others_1

    Time frame: the last record received before CVVH (in an average of 1 hour before CVVH treatment), the first record received CVVH after 24 hours (in an average of 1 hour after CVVH treatment), the first record received after CVVH (in an average of 1 hour after CVVH)

    body temperature

  11. others_2

    Time frame: the last record received before CVVH (in an average of 1 hour before CVVH treatment), the first record received CVVH after 24 hours (in an average of 1 hour after CVVH treatment), the first record received after CVVH (in an average of 1 hour after CVVH)

    platelet

Sponsors and collaborators

Lead sponsor

Taipei Medical University

Other

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Dec 6, 2022
Registry last updated
Dec 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.